Substituted nucleosides, nucleotides and analogs thereof

• US 10,144,755 B2
• Filed: 09/02/2016
• Issued: 12/04/2018
• Est. Priority Date: 12/21/2012
• Status: Active Grant

• Current Assignee: Janssen Biopharma, Inc. (Johnson & Johnson)
• Original Assignee: Alios Biopharma, Inc. (Johnson & Johnson)
• Inventors: Beigelman, Leonid, Wang, Guangyi, Smith, David Bernard
• Primary Examiner(s): McIntosh, III, Traviss C
• Application Number:
  US15/256,345
• Publication Number:
  US 20170037075A1
• Time in Patent Office: 823 Days
• Field of Search: None
• CPC Class Codes: A61K 31/7076 containing purines, e.g. adenosine, adenylic acid
• CPC Class Codes: A61P 31/14 for RNA viruses
• CPC Class Codes: C07H 19/06 Pyrimidine radicals
• CPC Class Codes: C07H 19/10 with the saccharide radical esterified by phosphoric or polyphosphoric acids
• CPC Class Codes: C07H 19/16 Purine radicals
• CPC Class Codes: C07H 19/173 with 2-deoxyribosyl as the saccharide radical
• CPC Class Codes: C07H 19/20 with the saccharide radical esterified by phosphoric or polyphosphoric acids
• CPC Class Codes: C07H 19/207 the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
• CPC Class Codes: C07H 19/213 containing cyclic phosphate

Abstract

Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs.

Claims

1. A compound selected from the group consisting of:

2. A compound selected from the group consisting of:

3. A compound selected from the group consisting of: